We have previously demonstrated that carnitine deficiency aggravated paracetamol-induced hepatopathy and carboplatin-induced nephropathy. As a continuum, we have addressed in the current study as to whether carboplatininduced myelosuppression would be exacerbated by carnitine deficiency. Challenging male Wistar rats with a single dose of carboplatin (35 mg/kg, IP) induced bone marrow suppression manifested as anemia, leucopenia, thrombocytopenia as well as increased frequencies of the micronucleated bone marrow cells; MPCE and MNCE with notable reduction in the P/N ratio. The platinum drug also elevated serum TNF-and reduced serum free and total carnitine levels. Besides, ATP levels in red and T cells were lowered. Likewise, the mitochondrial membrane potential in T lymphocytes was reduced following the use of the potentiometric dye; JC-1, and this was well correlated with cellular ATP production. Carnitine deficiency exacerbated carboplatin myelotoxicity as it exaggerated all biochemical, hematological and cytogenetic parameters. To address as to whether carnitine deficiency was a causative clue or merely a sequel of carboplatin myelotoxicity, L-carnitine was supplemented ahead of carboplatin challenege. Herein, L-carnitine mitigated all the biochemical, hematological and cytogenetic effects possibly via modulating the release of TNF-, cellular ATP production and restoring the mitochondrial membrane potential. Irrespective of the mechanisms involved, the current results may afford the potential role for carnitine supplementation as add-on nutraceutical in carboplatinbased chemotherapy.
INTRODUCTION
Carboplatin is the first of the second generation platinum compounds to gain wide spread use in oncological practice. Since its clinical introduction in 1981, carboplatin has proven efficacy in a variety of human malignancies including small-cell lung [1] , ovarian [2] , and head and neck [3] cancer. However the clinical usefulness of the platinum compound has been hampered by detrimental side effects with the most important of which being myelosuppression [4] .
Myelosuppression with its dual of anemia and neutropenia is responsible for chemotherapy delays, discontinuations and dose modifications [5] . The mechanism of platinum-induced myelosuppression is not fully explored. Carboplatin, however, was found to target the hematopoietic stem cell fraction [6] possibly via DNA cross-linking and generation of oxidative stress products [7] .
Carnitine deficiency, on the other hand, has been implicated in the pathogenesis of an array of organ maladies including diabetes [8] , epilepsy [9] and cardiovascular disorders [10] . Uremia-induced carnitine *Address correspondence to this author at the Department of Pharmacology and Toxicology, Faculty of Pharmacy, MTI University, Cairo, Egypt; Tel: +202-01001529178; Fax: +202-22014052; E-mail: hmmarafa@yahoo.com deficiency, which is magnified by dialysis, is also associated with anemia hyporesponsive to erythropoietin [11] .
L-carnitine is a naturally occurring quaternary ammonium compound, which is endogenously synthesized in man and also found in the diet [12] . It is cofactor of enzymes for the transformation of middleand long-chain fatty acids. It regulates carbohydrate metabolism, maintains cell membrane structure and cell viability and acts also as a scavenger of oxygen free radicals in mammalian tissues [13, 14] . Besides, it has been proved that L-carnitine and in particular its propionyl ester, stimulates erythropoiesis, which was expressed by a significant increase of erythroid progenitors in bone marrow and other hematopoietic organs [15] . Also, the observed relationship between carnitine serum level and osmotic erythrocyte fragility suggests indirectly its beneficial role in erythrocyte membrane stabilization [16] .
Taken together, the main objective of the present work was to address the role of carnitine deficiency in carboplatin-induced myelosuppression. This study was further extended to elucidate if carnitine supplementation would mitigate the myelotoxic and hematotoxic effects of the cytotoxic drug in an attempt to unravel the riddle as to whether carnitine deficiency is a possible forerunner or a consequence of such myelotoxicity.
In this sense, carnitine deficiency model was induced in rats by repeated administration of Dcarnitine which was used as an effective carnitine deficiency surrogate model for carnitine-deficient diet as it interferes with the normal absorption and disposition of the active L-form. Animals were challenged thereafter with a single IP dose of carboplatin. Myelosuppression was assessed hematologically, biochemically as well as by examination of bone marrow specimens. Herein, complete blood count (CBC) has been done with special emphasis on hemoglobin, neutrophils, and thrombocytes. Serum TNF-level was assessed as a proinflammatory cytokine. Cytogenetic examination of bone marrow specimens encompassed the determination of the number of polychromatic erythrocytes (PCE) and normochromatic erythrocytes (NCE) as well as the PCE/NCE ratio. The frequencies of micronucleated PCEs and NCEs have been computed as a measure of chromosomal damage. Cellular ATP levels in both red and T cells were determined as a measure of energy status. Measurement of mitochondrial potential was done in T lymphocytes since mitochondria play the primary role in energy production and ATP generation.
MATERIALS AND METHODS

Drugs
Carboplatin was obtained as ampoules from BristolMyers-Squibb (Princeton, NJ, USA). D-carnitine and Lcarnitine were purchased from Sigma-Aldrich (St. Louis, MO, USA) as white powder freely soluble in water.
Chemicals
Acetyl Coenzyme A (CoA) and carnitine acetyltransferase were supplied by Roche Diagnostics (Barcelona, Spain). Giemsa's and May-Gruenwald's solutions were purchased from Merck (Darmstadt, Germany). All other chemicals were of the finest analytical grade.
Animals
Male Wistar rats weighing 150-180 g were obtained from Theodor Bilharz Institute (Giza, Egypt). Animals were housed in the animal facility of the Pharmacy College, Al-Azhar University in Cairo. The animals were kept at temperature of 21 ºC and a relative humidity of 55% with a regular 12 h light/12 h dark cycle. The animals were fed standard chow (El-Nasr Co., Abou-Zaabal, Cairo, Egypt), and allowed free access to water. All animal experiments were conducted according to the regulations of the Committee on Bioethics for Animal Experiments of AlAzhar University.
Design of Work
A total of sixty male Wistar rats were allotted in six groups; ten animals each. Treatment regimens were assigned as such: (1) A group was given distilled water (0.2 ml/100 g bd. wt., IP) once daily for 10 consecutive days. (2) A second group was administered D-carnitine (250 mg/kg bd. wt., IP) once daily for ten consecutive days [17] . (3) A third group was challenged with a single dose of carboplatin (35 mg/kg bd. wt., IP). (4) A fourth group was given D-carnitine as before followed thereafter by carboplatin in the same dose regimen. (5) A fifth group received L-carnitine (500 mg/kg, IP) for 10 consecutive days [18] . (6) A sixth group was administered L-carnitine and then challenged with carboplatin as before.
Retro-orbital blood samples were withdrawn under light ether anesthesia using heparinized microcapillaries (Optilab, Berlin, Germany) 6 days after carboplatin administration. Thereafter, animals were euthanized by cervical dislocation and terminally bled. Heparinized blood was used for assessment of hematological parameters. Serum was separated following centrifugation at 500 g for 10 min at 4 C and used for carnitine and TNF-analysis. Rest of blood was used for separation of RBCs and T cells. Bone marrow was separated from femurs and processed as in methodology prior to micronucleus assay.
Assessment of Carnitine Levels
Total and free carnitine concentrations were determined in serum according to the method reported by Prieto et al. [19] . In brief, carnitine reacts with acetylCoA catalyzed by carnitine acetyltransferase. The coenzyme A liberated combines with 5,5-dithiobis-(2-nitrobenzoic acid) (DTNB) and forms thiophenolate ion, whose generation is proportional to the amount of carnitine and can be measured spectrophotometrically at 412 nm. For total carnitine assay, the method requires precipitation of proteins with 0.6 M perchloric acid, followed by alkaline hydrolysis of acylcarnitines. Carnitine level was computed from a calibration curve for carnitine hydrochloride.
Determination of raTNF-Concentration in Rat Serum
Serum raTNF-was assessed using a commercial kit purchased from Biosource International (California, USA). It is a solid phase sandwich enzyme-linked immunosorbent assay (ELISA). The assay method was preformed utilizing the principle of immuno-sorbent assay previously described by Wolters et al. [20] . The color intensity measured at 450 nm is directly proportional to the concentration of raTNF-present in the original specimen.
Micronucleus Assay
The micronucleus test in erythrocytes of rat bone marrow was proposed as a screening test by Von Ledbur and Schmid [21] . The main purpose of the test is to determine the number of micronucleated PCEs. The frequency of micronuclei can be most easily evaluated in young erythrocytes shortly after the main nucleus is expelled. These young erythrocytes are termed polychromatic (PCE) and are distinguished from the mature normochromatic (NCE) ones by their different staining properties. With a combination of Giemsa and May-Gruenwald staining [22] the PCEs stain bluish to purple due to their high content of RNA in the cytoplasm. In contrast, the NCEs stain reddish to yellow and are also slightly smaller than PCEs. The ratio of NCE to PCE is determined by counting a total of about 2000 erythrocytes per slide including both NCEs and PCEs. From each slide, PCEs and NCE cells were examined for MPCEs and MNCE under 1000x magnification using an Olympus microscope (PA, USA). In addition, the numbers of PCEs and NCEs per slide were recorded to evaluate bone marrow toxicity; PCE (P): NCE (N) ratio was calculated as % PCE = [PCE/ (PCE + NCE)] x 100 to determine a reduction of erythroblast proliferation.
Luciferease-Luminescence ATP Assay
The level of ATP in T cells and RBCs was determined according to Mikirova et al. [23] using a commercial CellTiter-GloLuminescent cell Viability Assay kit (Promega, USA). The assay generates a glow type signal produced by luciferase reaction, which is proportional to the amount of ATP present in cells. In this assay, the signal half-life was greater than one hour. For photon count, 50 microL of reaction mixture was mixed with 50 microL of cells and the count was measured by luminometer (BD Biosciences, USA). RBCs were separated from other cells and plasma by centrifugation at 500 g for 10 min. The supernatant and "buffy coat" were removed by aspiration. Packed cells were diluted by PBS with 10 mM glucose and 1mg/ml BSA (bovine serum albumin) to preserve the normal shape of RBCs. The RBCs were then washed two times by PBS and centrifuged at 200 g for 2-3 min. The final dilution of cells by PBS was greater than 1:3000. Before ATP measurements, cells were counted by hemo-cytometer (Neubauer, Berlin, Germany). T cells were separated by "PosetteSep" procedure from Stem Cell Technology (USA). In this procedure, 50 microL of RosetteSep cocktail was added to each mL of blood and mixed well. Cells were incubated 20 min at room temperature. After incubation, cells were diluted with an equal volume of PBS containing 2% FBS (fetal bovine serum), mixed well and layered on the top of FicollPaque (Amersham Bioscience). After 20 min of centrifugation at 1200 g, enriched cells were separated, washed in PBS with FBS, counted, and used for analysis. For determination of the standard curve, ATP (Sigma-Aldrich, USA) was dissolved in PBS to make concentrations of 50-500 nM. ATP was measured in nM/1 x 10 6 cells.
Assessment of Mitochondrial Membrane Potential
Mitochondrial potential was assessed by using the fluorescent potentiometric dye, JC-1 (5,52,6,62,-tetrachloro-1,12,3,32 tetraethylbenzimidazolylcarbocyanine iodide) as described earlier by Cossarizza et al. [24] . JC-1 is able to selectively enter the mitochondria of intact cells and form aggregates that emit at 585 nm. If the mitochondrial potential is reduced, JC-1 disaggregates to monomers that fluoresce at 527 nm. The ratio between both signals is indicative of the mitochondrial potential. Emission was measured by fluorescence plate reader (SPEX Instruments, IL, USA) at excitation 510 nm in the scan range of 520-600 nm.
Hematological Parameters
Complete blood count (CBC) was assessed to determine the numbers or proportions of white and red blood cells in the body. Cell counting was achieved by aperture impedance method (Coulter-Counter technique) that was earlier described by Coulter [25] . Blood samples were mixed with 10 microL EDTA and then placed in Swelab's fully automatic auto-counter, model AC920EO+ (Cape Town, South Africa). Up to 15 parameters were simultaneously counted.
Statistical Analysis
Statistical analysis was accomplished using GraphPad InStat (version 3.10, Philadelphia, USA, 2009). Data were computed as mean ± SE. Multiple comparisons of parametric data were achieved using one way ANOVA followed by Tukey as post-hoc test. Correlation analysis was done by calculating Pearson r. The criterion for significance was chosen to be p < 0.05.
RESULTS
Serum Carnitine Level
Total and free serum carnitine levels are compiled in Table 1 . D-carnitine reduced total and free carnitine levels by 63 and 58% respectively, compared to control values. Carboplatin reduced total and free carnitine levels by 28 and 32% respectively, compared to control group. Prior administration of D-carnitine ahead of carboplatin challenge resulted in serum nadir of total and free carnitines amounted to 86 and 85 % respectively, compared to control levels. The combination modality also reduced the serum total and free carnitine levels by 81 and 79%, respectively compared to carboplatin-treated animals, and by 62 and 65 % compared to D-carnitine-treated rats.
Serum raTNF-Concentration
D-carnitine increased serum TNF-concentration by 32 % compared to control rats (Figure 1a) . Administration of carboplatin resulted in significant increase in serum TNF-by 153 % compared to control animals (Figure 1a) . Prior administration of Dcarnitine before carboplatin caused substantial increase in serum TNF-amounted to about 206 % compared to control group (Figure 1a) . Also, the combination modality increased the serum cytokine level by about 21 and 132% respectively, compared to carboplatinand D-carnitine-treated animals, respectively. L-carnitine had no effect on serum TNFconcentration compared to control level (Figure 1b) . Pretreatment with L-carnitine before carboplatin, however, resulted in marked decrease in serum TNFconcentration by 58 % compared to animals treated with carboplatin alone.
Assessment of the Cytogenetic Effects
Effects of carnitine isomers and/or carboplatin on the frequencies of of PCE and NCE and their micronucleated erythroblasts as well as the P/N ratio in the bone marrow of male Wistar rats are shown in Tables 2-3 . D-carnitine had no effect on the frequencies of either PCE or NCE cells let for the significant occurrence of micronucleated erythroblasts. Carboplatin, however, significantly reduced the number of PCE by about 14% and increased the count of NCE by about 13% compared to control values. Besides, the P/N ratio was reduced by about 23 % compared to control ratio ( Table 2 ). The number of micronucleated cells; MPCE and MNCE, was increased by 139 and 138 % respectively, compared to control group ( Table  2) . Prior administration of D-carnitine before carboplatin resulted in significant decrease in P/N ratio by 32% compared to control value, and 12% compared to carboplatin-challenged animals ( Table 2 ). The combination modality also increased the incidence of MPCE and MNCE by 239 and 217%, respectively compared to control values and by 42 and 33% compared to carboplatin-treated rats ( Table 2 ). Lcarnitine had no effect on the number of either PCE or NCE let for the P/N ratio compared to control group (Table 3) . Further, it did not affect the incidence of micronucleated erythroblasts compared to control values ( Table 3) . Pretreatment with L-carnitine before carboplatin resulted in a significant increase in the P/N Carboplatin (35 mg/kg, IP) was given as a single dose. 4 Animals were challenged with carboplatin as before after repeated D-carnitine administration.
-Multiple comparisons were accomplished using one way ANOVA followed by Tukey as a post-hoc test. ratio amounted to 13% compared to rats treated with carboplatin alone. The combined regimen also reduced the frequencies of MPCE and MNCE by 39 and 37%, respectively compared to carboplatin-treated animals ( Table 3) .
ATP Levels in Red and T Cells
D-carnitine lowered ATP levels in red cells and T cells by 50 and 44 %, respectively compared to control values (Figure 2a) . ATP levels in red cells and T cells were reduced by 39 and 27 %, respectively compared to control animals following carboplatin challenge. Dcarnitine followed thereafter by carboplatin notably reduced cellular ATP levels by about 71 and 64 % compared to control group; and 49 and 50 %, respectively compared to carboplatin-treated rats (Figure 2a) . L-carnitine increased cellular ATP levels by 54 and 33% compared to control values (Figure 2b) . Prior administration of L-carnitine ahead of carboplatin injection significantly increased cellular ATP levels in both cell types by 36 and 32 % respectively, compared to carboplatin-treated group (Figure 2b) .
Mitochondrial
Membrane Potential in T Lymphocytes D-carnitine lowered the mitochondrial membrane potential in T cells by about 37.5 % compared to control value (Figure 3) . Carboplatin reduced the Control animals received distilled water in a dose of 0.2 ml/100 g, IP.
2 L-carnitine (500 mg/kg body weight, IP) was given for 10 consecutive days ahead of carboplatin challenge. membrane potential by about 25 % compared to control group. Challenging animals with carboplatin following D-carnitine administration resulted in reduced membrane potential amounted to about 63, 50 and 40% compared to control-, carboplatin-, and Dcarnitine-treated animals, respectively. Pretreatment with L-carnitine before the platinum drug increased the membrane potential by 22% compared to carboplatin group. There was also a positive correlation between ATP level in T cells and the mitochondrial membrane potential with a Pearson value (r) of 0.844 (Figure 4) .
Effects on Hematological Parameters
Hematological parameters following different treatment regimens that incorporated carboplatin with either D-carnitine or L-carnitine are compiled in Tables  4,5 . D-carnitine had no effect on CBC compared to control values. Carboplatin, however, altered all the blood elements tested. Carboplatin provoked notable nadirs in hemoglobin content (Hb), RBCs, PLT and WBC counts by about 21%, 31%, 44% and 35%, respectively compared to control rats. Prior administration of D-carnitine before carboplatin produced marked decreases particularly in Hb content, RBCs, PLT and WBC counts amounted to about 36%, 40%, 52% and 43%, respectively compared to control animals, 34%, 38%, 49% and 37%, respectively compared to rats given D-carnitine alone, and, 18%, 13%, 15% and 12%, respectively compared to carboplatin-treated rats. L-carnitine had no effect on CBC compared to control rats. Pretreatment with Lcarnitine before carboplatin increased most of the blood elements levels particularly Hb content, RBCs, PLT and WBC counts by about 20 %, 15%, 12% and 12%, respectively compared to animals treated with carboplatin alone. Carboplatin (35 mg/kg body weight, IP) was administered once and blood samples were withdrawn after 6 days. 4 D-carnitine was given as before followed thereafter by carboplatin in the same dose regimen and blood samples were withdrawn after 6 days. 
DISCUSSION
Carboplatin is one of the most active cytotoxic agents in current use. However, the clinical utility of the platinum compound has been precluded by untoward effects with the most important of which being myelosuppression [4] .
Challenging animals with a single dose of carboplatin induced myelotoxicity that was characterized biochemically, hematologically as well as by cytogenetic analysis of bone marrow samples.
Carboplatin provoked marked reductions in almost all blood elements leading ultimately to anemia, thrombocytopenia, leucopenia and neutropenia. This is coping with many earlier reports that documented such bone marrow suppression [26, 27] . The exact mechanism whereby the platinum compound would exert such an effect is not fully explored. However, the finding in the current study that carboplatin notably increased serum TNFlevel may explain such myelotoxicity. Earlier study by Ulich et al. demonstrated that TNF-alpha was a potent inhibitor of erythropoiesis, and the cytokine has been shown in vitro to inhibit the growth of erythroid and myeloid progenitors [28] . TNF alpha and its soluble receptors may be involved in the pathogenesis of drug-induced myelosuppression [29] . The apparent reduction in cellular ATP levels in red and T cells and the decreased mitochondrial membrane potential in T cells following carboplatin challenge, which was correlated well with the ATP nadir observed in lymphocytes may provide an explanation for the myelotoxic, hematotoxic and genotoxic effects of carboplatin. This may be explained in light of the deterioration in membrane potential that led to mitochondrial disruption, which is a distinctive early feature of cellular apoptosis. D-Carnitine increased serum TNF-and reduced both cellular ATP content and mitochondrial membrane potential. We have reported similar elevations in serum levels of the proinflammatory cytokine in carnitinedeficient rats [17, 30] . Cellular deterioration of ATP may be due to the deficiency in carnitine; the fatty acids transport carrier that carries fatty acids from cytosol into mitochondria to be metabolized by beta oxidation to release ATP through citric acid cycle.
Carnitine deficiency exacerbated carboplatininduced anemia, leucopenia and thrombocytopenia. Herein, it was reported that nutritional carnitine deficit Data are presented as means ± SEM, n = 10.
1
Control Animals received distilled water in a dose of 0.2 ml/100 g, IP.
2 L-carnitine (500 mg/kg body weight, IP) was given for 10 consecutive days ahead of carboplatin challenge. Carboplatin (35 mg/kg body weight, IP) was administered once and blood samples were withdrawn after 6 days. 4 L-carnitine was given as before followed thereafter by carboplatin in the same dose regimen and blood samples were withdrawn after 6 days. would alter erythropoiesis [31] . Blocking by D-carnitine of the crucial role of endogenous L-carnitine in the transport of free fatty acids to the mitochondrial metabolic machinery in bone marrow cells, as energy source for erythropoiesis, cannot be excluded as a possible mechanism.
Carnitine deficiency prior to carboplatin challenge notably increased the number of micronucleated cells in both PCE and NCE cells. It also decreased the P/N ratio. This again confirms the potentiative effects of carnitine deficiency on carboplatin myelotoxicity.
The finding that L-carnitine has been shown to prolong RBC lifespan and to abrogate anemia in animal and human studies including hemodialysis patients beside its beneficial effects on erythropoiesis [32] warranted our attention to address in the current study the postulate as to whether carnitine deficiency would possibly exacerbate carboplatin myelosuppression. The study was further extended to unravel the presumable protective role of carnitine replenishment in this toxicity paradigm in an attempt to clarify the conundrum as to whether carnitine deficiency is a causative clue or a sequela for carboplatin myelotoxicity.
Carnitine replenishment improved myelotoxicity as manifested by correction of anemia, leucopenia and thrombocytopenia. It also apparently reduced serum TNF-alpha level and reduced the percentage of micronucleated cells in both PCE and NEC populations when administered ahead of carboplatin challenge. The P/N ratio was also significantly reduced. This finding is in line with previous reports that demonstrated anticlastogenic effects of carnitine [33, 34] . Also, Abd-Allah et al. [35] have also demonstrated a protective role of carnitine in bone marrow cells following exposure to carboplatin.
Based on the broad observations in this study, one could conclude that carnitine deficiency exacerbated carboplatin myelosuppression and consequently hematotoxicity presumably via increasing TNFproduction, altering mitochondrial membrane potential alongside with reduced ATP production. By doing that, it would possibly pose a further burden on subjects undergoing carboplatin-based chemotherapy. The notion that carnitine replenishment was able to effectively mitigate such myelotoxicity and correct the hematotoxic effects of the platinum drug when given ahead of carboplatin challenge would warrant our attention to the interesting possibility of using such nutraceutical as adjunctive add-on agent in chemotherapeutic armamentarium.
